Follow-up of cyclosporin A treatment in type 1 (insulin-dependent) diabetes mellitus: lack of long-term effects
| Autor: | Eberhard Standl, Jørn Nerup, Calvin R. Stiller, M. H. Tan, R. McArthur, K. Dawson, John Dupre, B. von Graffenried, Veikko A. Koivisto, F. A. Gries, Hubert Kolb, P. Hamet, Guntram Schernthaner, S. Martin, A. E. Mehta, S. Van Vliet |
|---|---|
| Rok vydání: | 1991 |
| Předmět: |
Adult
Male medicine.medical_specialty Time Factors Adolescent Endocrinology Diabetes and Metabolism 030209 endocrinology & metabolism Blood Pressure Cyclosporins Placebo Gastroenterology law.invention 03 medical and health sciences Hemoglobins Islets of Langerhans 0302 clinical medicine Randomized controlled trial Double-Blind Method law Cyclosporin a Diabetes mellitus Internal medicine Internal Medicine medicine Humans Adverse effect Child 030304 developmental biology 0303 health sciences Type 1 diabetes business.industry medicine.disease Creatine 3. Good health Discontinuation Blood pressure Endocrinology Diabetes Mellitus Type 1 Potassium Female business Follow-Up Studies |
| Zdroj: | Diabetologia. 34(6) |
| ISSN: | 0012-186X |
| Popis: | In the Canadian/European randomized controlled study on cyclosporin A (CsA) in recent onset Type 1 (insulin-dependent) diabetes, treatment with the immunosuppressive drug had increased and maintained Beta-cell function and clinical remission during the first 12 months. Following discontinuation of the study drug and double-blinding after a mean of 13.8 months former CsA patients doubled the daily insulin dose within 6 months reaching the level of former placebo patients. The difference in Beta-cell function between the two groups was also lost. Metabolic control (HbA1c) was transiently worse in the former CsA group. Adverse effects of cyclosporin A on systolic blood pressure, haemoglobin levels, serum potassium and creatinine levels also remitted during that time. We conclude that treatment with cyclosporin A for a mean of 13.8 months had no long-lasting effect on the course of Type 1 diabetes persisting beyond drug discontinuation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink